Sorrento Therapeutics (Sorrento Therapeutics) Total Inventories : $9.65 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Sorrento Therapeutics Total Inventories?

Sorrento Therapeutics's total inventories for the quarter that ended in Jun. 2023 was $9.65 Mil. Sorrento Therapeutics's average total inventories from the quarter that ended in Mar. 2023 to the quarter that ended in Jun. 2023 was $10.48 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Sorrento Therapeutics's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-1.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Sorrento Therapeutics's Days Inventory for the three months ended in Jun. 2023 was 113.13.

Inventory Turnover measures how fast the company turns over its inventory within a year. Sorrento Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2023 was 0.81.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sorrento Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.70.

Sorrento Therapeutics Total Inventories Historical Data

The historical data trend for Sorrento Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Total Inventories Chart

Sorrento Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Inventories

Get a 7-Day Free Trial

2.90

3.36

1.83

8.11

9.98

Sorrento Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Inventories	Get a 7-Day Free Trial															20.70	17.96	9.98	11.31	9.65

Sorrento Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Sorrento Therapeutics (OTCPK:SRNE) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Sorrento Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is

	Net-Net Working Capital Per Share (Q: Jun. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(80.635	+	0.75 * 32.725	+	0.5 * 9.651	-	654.648
-	0	-	7.157)	/	551.281
=	-1.00

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sorrento Therapeutics's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2023 )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
	=	10.4795	/	8.453	*	365 / 4
	=	113.13

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sorrento Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2023 )	/	Average Total Inventories (Q: Jun. 2023 )
	=	8.453	/	10.4795
	=	0.81

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sorrento Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	10.4795	/	15.025
	=	0.70

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Sorrento Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Sorrento Therapeutics (Sorrento Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (OTCPK:SRNE) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

4955 Directors Place, San Diego, CA, USA, 92121

Website

https://www.sorrentotherapeutics.com

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Executives

Henry Ji	director, officer: See Remarks	5370 RUETTE DE MER, SAN DIEGO CA 92130
Tammy Reilly	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Kim Janda	director	6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Elizabeth Czerepak	director	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Dorman Followwill	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Najjam Asghar	officer: Chief Financial Officer	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Robin L Smith	director	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Edgar Lee	director	C/O OAKTREE CAPITAL MANAGEMENT, L.P., 333 SOUTH GRAND AVE, 28TH FLOOR, LOS ANGELES CA 90071
Jerome B Zeldis	officer: See Remarks	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Jaisim Shah	director	C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
David Lemus	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Abg Management Ltd	10 percent owner	UNIT 3002-04,30TH FLOOR,GLOUCESTER TOWER, THE LANDMARK,15 QUEEN'S ROAD CENTRAL, HONG KONG K3 000000
Jiong Shao	officer: Chief Financial Officer	SUITE 1003-1004, 10/F, ICBC TOWER, THREE GARDEN ROAD, CENTRAL, HONG KONG F4 000000
George K Ng	officer: See Remarks	C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121